A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions
Phase 3
- Conditions
- Malignant Pleural Effusion
- Interventions
- Drug: ENDOSTAR，cisplatin
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2021-06-04
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 290
- Registration Number
- NCT04914598
- Locations
- 🇨🇳
Xiaoying Wang, Shanghai, China
A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer
Phase 3
Active, not recruiting
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 421
- Registration Number
- NCT04908787
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients
Phase 3
Completed
- Conditions
- Extensive-stage Small-cell Lung Cancer
- Interventions
- Drug: Trilaciclib, carboplatin, etoposide，or TopotecanDrug: placebo, carboplatin, etoposide，or Topotecan
- First Posted Date
- 2021-05-26
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 95
- Registration Number
- NCT04902885
- Locations
- 🇨🇳
Jilin Cancer Hopspital, Changchun, China
A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome.
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2021-07-19
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 144
- Registration Number
- NCT04830644
- Locations
- 🇨🇳
Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China
🇨🇳The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳Tianjin First Central Hospital, Tianjin, Tianjin, China
An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.
Phase 1
- Conditions
- Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion
- Interventions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2021-01-13
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 243
- Registration Number
- NCT04671849
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors
Phase 1
- Conditions
- Solid TumorNSCLC
- Interventions
- Drug: Pegylated Recombinant Human Endostatin（PEG-ENDO）
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT04413227
- Locations
- 🇨🇳
Tianjin medical university cancer institute&hospital, Tianjin, Tianjin, China
🇨🇳Beijing Hospital, Beijing, Beijing, China
A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.
- First Posted Date
- 2018-12-04
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT03763123
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Wuhan Union Hospital, Wuhan, Hunan, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
A Pilot Bioequivalence Study of Pomalidomide
Phase 1
Completed
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT03424928
- Locations
- 🇨🇳
The second hospital of shanxi medical university, Taiyuan, Shanxi, China
Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2016-09-27
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 73
- Registration Number
- NCT02916420
- Locations
- 🇨🇳
Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, China
Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously
- First Posted Date
- 2016-06-17
- Last Posted Date
- 2016-12-06
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT02805010
© Copyright 2025. All Rights Reserved by MedPath